MARTINSRIED, Germany, April 23, 2009 (GLOBE NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) will publish its first three months' 2009 results on April 28, 2009 at 7:00 a.m. CET.
At 2:00 p.m. CET (1:00 p.m. GMT, 8:00 a.m. EDT), the Management Board of MorphoSys AG will host a public conference call to present MorphoSys's financial results for the first three months of 2009 and provide further details on the Company's latest developments.
Dial-in numbers (listen only): Germany: +49 (0) 69 710491462 United Kingdom: +44 (0) 1212 604860 USA: +1 (1) 866 347 1957
An audio replay and manuscripts of the conference will be available on www.morphosys.com/conferencecalls in the afternoon of the same day.
About MorphoSys:
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit http://www.morphosys.com/
HuCAL(r), HuCAL GOLD(r), HuCAL PLATINUM(r) and RapMAT(r) are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
Conference Call Invitation (PDF)